Loading...
Protagonist Therapeutics, Inc.
PTGX•NASDAQ
Healthcare
Biotechnology
$55.15
$1.41(2.62%)
Protagonist Therapeutics, Inc. (PTGX) Financial Performance & Income Statement Overview
Review Protagonist Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
624.05%
↑ 624.05%
Operating Income Growth
369.98%
↑ 369.98%
Net Income Growth
448.54%
↑ 448.54%
Operating Cash Flow Growth
362.19%
↑ 362.19%
Operating Margin
13.10%
↑ 13.10%
Gross Margin
99.28%
↑ 99.28%
Net Profit Margin
27.04%
↑ 27.04%
ROE
9.22%
↑ 9.22%
ROIC
3.85%
↑ 3.85%
Protagonist Therapeutics, Inc. (PTGX) Income Statement & Financial Overview
Review Protagonist Therapeutics, Inc.'s (PTGX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $170.64M | $4.67M | $4.17M | $254.95M |
| Cost of Revenue | $604000.00 | $0.00 | $892000.00 | $820000.00 |
| Gross Profit | $170.03M | $4.67M | $3.27M | $254.13M |
| Gross Profit Ratio | $1.00 | $1.00 | $0.79 | $1.00 |
| R&D Expenses | $34.90M | $35.97M | $33.52M | $33.73M |
| SG&A Expenses | $8.95M | $10.16M | $8.55M | $14.09M |
| Operating Expenses | $43.86M | $46.13M | $42.07M | $47.82M |
| Total Costs & Expenses | $43.86M | $46.13M | $42.96M | $48.64M |
| Interest Income | $6.85M | $7.68M | $7.40M | $4.38M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $604000.00 | $647000.00 | $892000.00 | $820000.00 |
| EBITDA | $127.32M | -$40.81M | -$38.79M | $207.13M |
| EBITDA Ratio | $0.75 | -$8.73 | -$9.31 | $0.81 |
| Operating Income | $126.78M | -$41.45M | -$38.79M | $206.31M |
| Operating Income Ratio | $0.74 | -$8.87 | -$9.31 | $0.81 |
| Other Income/Expenses (Net) | $6.88M | $7.82M | $7.50M | $4.36M |
| Income Before Tax | $133.66M | -$33.63M | -$31.29M | $210.67M |
| Income Before Tax Ratio | $0.78 | -$7.19 | -$7.51 | $0.83 |
| Income Tax Expense | $1.99M | -$420000.00 | -$676000.00 | $3.33M |
| Net Income | $131.67M | -$33.21M | -$30.62M | $207.34M |
| Net Income Ratio | $0.77 | -$7.10 | -$7.35 | $0.81 |
| EPS | $2.14 | -$0.54 | -$0.50 | $3.41 |
| Diluted EPS | $2.02 | -$0.54 | -$0.50 | $3.26 |
| Weighted Avg Shares Outstanding | $62.33M | $61.77M | $61.31M | $60.86M |
| Weighted Avg Shares Outstanding (Diluted) | $66.41M | $61.77M | $61.31M | $63.60M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan